A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cobimetinib (Primary) ; Ipatasertib (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Selicrelumab (Primary) ; Carboplatin; Eribulin; Gemcitabine; Paclitaxel; Sacituzumab govitecan; Tocilizumab
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Morpheus-panBC
Sponsors Genentech; Roche

27 Aug 2024 Planned number of patients changed from 312 to 580.
27 Aug 2024 Planned End Date changed from 3 May 2026 to 3 May 2028.
27 Aug 2024 Planned primary completion date changed from 3 May 2026 to 3 May 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com